BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

Дата публикации: 07-08-2026 23:08:03

Lund, Sweden – August 7, 2026 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a leader in the discovery of novel immune-modulatory antibodies, today announces that the U.S. Food and Drug Administration...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer	0	17.15	20-07-2026
2	Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors	0	13.2	08-07-2026
3	Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors	0	11.39	29-04-2026
4	FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer	0	17.03	14-07-2026
5	Ascelia Pharma Provides Update on the Orviglance NDA	0	11.3	03-07-2026
6	Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy	0	17.81	03-08-2026
7	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
8	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD	0	10.76	16-06-2026
9	Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma	0	12.59	10-07-2026
10	Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod	0	18.01	30-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.23. Источник: www.drugs.com.